cannabis rescheduling

The potential impacts of rescheduling have dominated cannabis discourse over the last four weeks. MSOs and other plant-touching companies have had their greatest percentage gains in two years despite a meaningful correction last week. The Charts delve into the trailing 4-week percentage gains in...

One of the most important results of the potential rescheduling of cannabis to Schedule 3 is eliminating 280e taxes. In previous charts of the week, we have shown that 280e significantly negatively impacts cannabis companies by reducing their internally funded growth and limiting their debt...

The AdvisorShares Pure US Cannabis ETF (NASDAQ: MSOS) surged by more than 14% on Thursday as the whole cannabis sector experienced a boost of enthusiasm on news that the Department of Health and Human Services was officially directing the DEA to ease the onerous...

New York Senator Chuck Schumer (D) responded to Wednesday's news that the Dept. of  Health and Human Services wrote to DEA administrator Anne Milgram calling for marijuana to be reclassified as a Schedule III drug under the Controlled Substances Act.  Cannabis'...